DCC4697 |
Sfom-0046 |
Novel anticancer agent, arresting cell cycle in S-phase and causes DNA replication stress leading to the phosphorylation of H2AX into gamma-H2AX |
|
DCC4698 |
Sfrp-1 Inhibitor-1 |
Cell-permeable antagonist of secreted frizzled related protein-1(sFRP-1), inhibiting Wnt-3/frizzled interaction and restoring cellular response to Wnt-3 stimulation |
|
DCC4699 |
Sfti-1 |
Highly Potent and Selective Plasmin Inhibitor, Attenuating Fibrinolysis in Plasma |
|
DCC4700 |
Sgc-camkk2-1 |
Novel probe for CAMKK2/CAMKK1 |
|
DCC4701 |
Sgc-clk-1 |
Novel probe for CLK1, CLK2, and CLK4 |
|
DCC4702 |
Sgc-gak-1n |
Negative control for SGC-GAK-1 (GLXC-31266) |
|
DCC4703 |
Sge201 |
Novel potent allosteric modulator of N-methyl-D-aspartate receptors (NMDAR) |
|
DCC4704 |
Sgi-10067 |
PKM2 activator, potently inhibiting proliferation of cancer cells in media lacking serine |
|
DCC4705 |
Sgi-9380 |
PKM2 activator, potently inhibiting proliferation of cancer cells in media lacking serine |
|
DCC4706 |
Sgk1 Inhibitor 17a |
Novel highly selective SGK1 inhibitor with a highly optimized profile suitable for oral dosing as a potentially disease-modifying agent for osteoarthritis |
|
DCC4707 |
Sglt1/2-in-8 |
Novel Potent SGLT1/2 Dual Inhibitor |
|
DCC4708 |
Sgx393 |
Novel inhibitor of the CML mutant Bcr-AblT315I, preempting in vitro resistance when combined with nilotinib or dasatinib. |
|
DCC4709 |
Sh-053-r-ch3-2’f |
Selective agonist of GABA A receptors α5 subunit |
|
DCC4710 |
Sh-053-s-ch3-2'f |
Potent and selective agonist of GABAA receptors α5 subunit |
|
DCC4711 |
Sh-11037 |
Novel potent sEH inhibitor, effectively blocking key angiogenic properties of human retinal endothelial cells (HRECs), inhibiting choroidal sprouting and significantly suppressing CNV lesion volume |
|
DCC4712 |
Sh-11052 |
Novel inhibitor of endothelial cell growth |
|
DCC4713 |
Sh-2251 |
Novel selective inhibitor of the generation of IL-5-producing Th2 cells and induction of active histone modifications at the IL5 gene locus during Th2 cell differentiation |
|
DCC4714 |
Sha 14-1 |
Stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypassing drug resistances and synergizing cancer therapies in human leukemia cell |
|
DCC4715 |
She-196 |
First in Class Hypoglycemic Agent with Extra-Strong Action, increasing insulin sensitivity, improving glucose tolerance, reducing fasted insulin level and insulin sensitivity, decreasing total body and interscapular fat mass and also increasing the activi |
|
DCC4716 |
Sherpa Bmi-135 |
Novel Selective Human ER Partial Agonist (ShERPA) |
|
DCC4717 |
Sheta2 |
Selective inhibitor of cancer cell growth, exerting chemoprevention activity without evidence of toxicity |
|
DCC4718 |
Sh-i-14 |
Novel Inhibitor of Phospho-STAT3 Through Induction of Protein Tyrosine Phosphatase PTPN6 |
|
DCC4719 |
Shield-2 |
Novel potent stabilizing ligand for FKBP-derived destabilizing domains |
|
DCC4720 |
Ship-2a |
Cystathione gamma lyase (CSE) inhibitor, inhibiting H2S production and L-cysteine-induced relaxation of rat aortic rings ex vivo |
|
DCC4721 |
Showdomycin |
Antineoplastic antibiotic |
|
DCC4722 |
Shp2 Inhibitor C21 |
Inhibitor of shp2 protein tyrosine phosphatase (PTP) |
|
DCC4723 |
Shr0687 |
Highly Potent and Peripheral Nervous System-Restricted KOR Agonist |
|
DCC4724 |
Sibopirdine |
Novel cognitive enhancer; Nootropic agent |
|
DCC4725 |
Sid-24784551 |
Novel direct HIV-1 Nef antagonist with antiretroviral activity |
|
DCC4726 |
Sid-7977382 |
Novel Complement Factor C1 Inhibitor |
|